Last reviewed · How we verify

NCT04920851

Cytokine Hemadsorption in Covid 19 Patients With Bacterial Sepsis

Status unknown Last updated 10 June 2021
What this trial tests

trial testing cytokine hemadsorption in INTERLEUKIN 6 in 23 participants. Status unknown.

Timeline
10 June 2021
Primary endpoint
5 July 2021
20 July 2021

Quick facts

Lead sponsorDerince Training and Research Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment23
Start date10 June 2021
Primary completion5 July 2021
Estimated completion20 July 2021
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Derince Training and Research Hospital

Who can join

Adults 18 to 80, any sex, with INTERLEUKIN 6. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this retrospective study, we aimed to compare the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in COVID-19 ICU patients with or without sepsis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of cytokine hemadsorption

Trials testing the same drug.

Other Derince Training and Research Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04920851.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing